deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01181271

Tandem Auto-Allo Transplant for Lymphoma

Sequential Myeloablative Autologous Stem Cell Transplantation Followed by Allogeneic Non-Myeloablative Stem Cell Transplantation for Patients With Poor Risk Lymphomas

Sponsor: Dana-Farber Cancer Institute

Conditions Chronic Lymphocytic Leukemia Diffuse, Large B-Cell, Lymphoma Hodgkin's Lymphoma Lymphoma, Low-Grade Lymphoma, Small Lymphocytic Mantle-Cell Lymphoma T-Cell Lymphoma
Interventions Busulfan (conditioning for ALLO Transplant) Busulfan (conditioning for AUTO transplant) Cyclophosphamide (conditioning for AUTO transplant) Etoposide (conditioning for AUTO transplant) Fludarabine (conditioning for ALLO Transplant) Mesna (prior to AUTO transplant) Methotrexate Neupogen Sirolimus Tacrolimus autologous (auto) peripheral blood stem cell transplantation non-myeloablative allogeneic (allo) transplant
Updated 6 times since 2017 Last updated: Jan 19, 2017 Started: Aug 31, 2010 Primary completion: Feb 28, 2014 Completion: Feb 29, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Lymphocytic Leukemia and Diffuse, Large B-Cell, Lymphoma and is currently completed. Dana-Farber Cancer Institute leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~May 2017 · 4 months · monthly snapshotActive Not Recruiting~May 2017 – ~Jun 2018 · 13 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. May 2017 — Jun 2018 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 1 earlier version

  1. Jan 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • Massachusetts General Hospital
Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations